Haematologica

Article	Citations
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	146
Acute lymphoblastic leukemia cells are able to infiltrate the brain subventricular zone stem cell niche and impair neurogenesis	104
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	102
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	101
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	94
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	84
A <i>Grammastola spatulata</i> mechanotoxin-4 (GsMTx4)-sensitive cation channel mediates increased cation permeability in human hereditary spherocytosis of multiple genetic etiologies	76
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	74
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	74
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies	66
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	64
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia	59
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	56
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.	55
The first human acute myeloid leukemia genome ever fully sequenced	53
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	52
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	49
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	49
Acute myeloid leukemia at first relapse: approaching the precipice	48
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	47
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	46
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel	46
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action	45
Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis	42
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials	42

An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	42
Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis	41
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	39
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy	39
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?	38
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	38
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis	38
Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade	37
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	37
The possible role of mutated endothelial cells in myeloproliferative neoplasms	37
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	37
Specific inhibition of the transporter MRP4/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets	36
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	36
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	35
Asparaginase-associated hyperammonemia	35
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	34
CD47 expression in acute myeloid leukemia varies according to genotype	34
Running chromosome analysis in leukemia or not, upfront or later?	34
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma	33
Prehistory of chronic lymphocytic leukemia: clues from the B-cell receptor	33
Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry	33
Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine	32
First-line MAPK inhibition in pediatric histiocytosis: are we ready?	32
SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism	32
How we changed our approach to venous thromboembolism	31
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program	30
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia	30
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study	29
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myeloma	29
New bullets in the fight against cancer	29
Kinetics matter: prognostic implications of early bone marrow assessment in acute myeloid leukemia	28
Mechanical unloading aggravates bone destruction and tumor expansion in myeloma	28
Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments	28
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KM	28
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study	28
Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia	27
Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report	27
Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology	27
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy	27
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients	27
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies	26
TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia	26
The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease	26
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia	26
IgM monoclonal gammopathies of clinical significance: diagnosis and management	26
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients	26
Therapeutic targeting of endoplasmic reticulum stress in acute graft-<i>versus</i>-host disease	25
Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen	25
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial	24
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)	24

LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia	24
Treatment of lower-risk myelodysplastic syndromes	24
Mutations in the <i>RACGAP1</i> gene cause autosomal recessive congenital dyserythropoietic anemia type III	23
COVID-19 vaccine-induced adverse events predict immunogenicity among recipients of allogeneic hematopoietic stem cell transplantation	23
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis	23
Advocating prudent D-dimer testing: constructive perspectives and comments on ‘How we manage a high D-dimer’	23
Safe platelet count for lumbar puncture: are we being overcautious?	23
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase	23
Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of <i>PCM1::JAK2</i> with erythroblastic sarcoma: a case report and literature review	23
MAPK-kinase mutations and aortic lesions are associated with distribution of circulating monocytes in histiocytosis	23
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia	23
LNK/<i>SH2B3</i> as a novel driver in juvenile myelomonocytic leukemia	22
STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of <i>BCL2</i> and <i>BCLXL</i> following glucocorticoid treatment	22
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas	22
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia	22
Getting (T cells) ENGaged	22
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients	22
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia	22
COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination Short title: COVID-19 thromboembolism	22
Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia–lymphoma	22
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study	22
Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on vire	22
LSD1/KDM1A and GFI1B repress endothelial fate and induce hematopoietic fate in induced pluripotent stem cell-derived hemogenic endotheliums	21
Clonal evolution from B-cell acute lymphoblastic leukemia with <i>BCR::ABL1</i> multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell	21
αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes	21
Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria	20
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome	20
Aspirin is a life-saving drug for patients with acute myocardial infarction	20
Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria	20
Reply to the Comment on: “Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry”	20
Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation	20
Interleukin 4 promotes phagocytosis of murine leukemia cells counteracted by CD47 upregulation	20
Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP	20
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden	20
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Work	19
Teclistamab therapy for refractory type 1 cryoglobulinemia Teclistamab in type 1 cryoglobulinemia	19
The International Prognostic Index: still relevant 30 years later	19
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma	19
A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis	19
An investigation of germline variants of <i>HAVCR2</i> in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population	19
Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy	19
Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review	19
CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?	19
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials	18
Type I interferons: leukemia's old foe in the limelight again	18
Entities <i>versus</i> diseases: Myers <i>et al</i>. propose distinct aspects of adult T-cell lymphoma / leukemia.	18
Novel immunotherapies in multiple myeloma – chances and challenges	18
Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries	18
The relative importance of platelet integrins in hemostasis, thrombosis and beyond	18
The effects of cardio-selective β blockade on diastolic dysfunction in children with sickle cell disease	18
More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma	18
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome	18
A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment	18
von Hippel- Lindau syndrome-related congenital polycythemia and response to belzutifan	18
Duality of Nrf2 in iron-overload cardiomyopathy	18
Association of <i>NUDT15</i> gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review an	17
Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria	17
Adenosine signaling inhibits erythropoiesis and promotes myeloid differentiation	17
Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas	17
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.	17
Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia	17
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T	17
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy	17
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir	17
Introduction. Immunotherapy for childhood malignancies: the future is now	17
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma	16
Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma	16
Sex differences in progression of kidney disease in sickle cell disease	16
Leon's helmet	16
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-ce	16
Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myeloma-reactive CD8+ T-cells are shared between blood and marrow	16
Diagnostic challenges and proposed classification of myeloid neoplasms with overlapping features of thrombocytosis, ring sideroblasts and concurrent del(5q) and <i>SF3B1</i> mutations	16
Targeting Wnt signaling in acute myeloid leukemia stem cells	16
Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia	15
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome	15
Teclistamab <i>versus</i> B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis	15
Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia	15
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase	15
Functional, biochemical, molecular and clinical characterization of antithrombin c.1157T>C (p.Ile386Thr), a recurrent Polish variant with a founder effect	15
Home time among older adults with acute myeloid leukemia by therapy intensity	15

The E3 ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia	15
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?	15
Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade	15
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in 'off the shelf' chimeric antigen receptor T-cell therapies to widen transplant options	15
More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune	15
Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.	15
Amyloidogenic light chains impair plasma cell survival	15
Delving the depths of measurable residual disease negativity in acute myeloid leukemia	15
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma	15
Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding	15
Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children	14
Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortali	14
Response to the Comment: “Advocating prudent D-dimer testing: constructive perspectives and comments on “How we manage a high D-dimer”	14
Clinical and molecular features of <i>CBL</i>-mutated juvenile myelomonocytic leukemia	14
Sorting nexin 24 is required for α-granule biogenesis and cargo delivery in megakaryocytes	14
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings	14
Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States	14
CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis	14
Myeloma natural killer cells are exhausted and have impaired regulation of activation	14
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopo	14
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study	14
Somatic genetic alterations predict hematological progression in GATA2 deficiency	14
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors	14
m<sup>6</sup>A reader Ythdf3 protects hematopoietic stem cell integrity under stress by promoting the translation of <I>Foxm1</i> and <i>Asxl1</i> transcripts	14
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application	14
Factors associated with left ventricular hypertrophy in children with sickle cell disease: results from the DISPLACE study	13
Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis	13
Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with cli	13
Do it once, but do it right	13
Immunosuppression with post-transplant cyclophosphamide for allogeneic hematopoietic cell transplantation	13
MD-ALL: an integrative platform for molecular diagnosis of B-acute lymphoblastic leukemia	13
<i>BRCA1/2</i> mutations and <i>de novo</i> hematologic malignancies: true, true and not clearly related	13
Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance	13
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde	13
Ethnicity in systemic AL amyloidosis may impact risk stratification	13
RNA helicase DHX15 exemplifies a unique dependency in acute leukemia	13
The double-edged sword of adenosine	13
Enhancement of PRMT6 binding to a novel germline <i>GATA1</i> mutation associated with congenital anemia	13
Detection of <I>ABL1</I> kinase domain mutations in therapy-naïve <I>BCR-ABL1</I>-positive acute lymphoblastic leukemia	13
Arkadia: a new player in hematopoietic stem and progenitor cell development	13
Artificial intelligence-based Myelodysplastic Syndromes Score, 2022 classifications, and the Molecular International Prognostic Scoring System: a perfect match	12
Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, <i>TP53</i> alterations and poor prognosis	12
Phosphatase, Mg<sup>2+</sup>/Mn<sup>2+</sup> dependent 1B regulates the hematopoietic stem cells homeostasis via the Wnt/β-catenin signaling	12
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes	12
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter	12
Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A	12
<i>ASXL1</i> mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms	12
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial	12
Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin	12
Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement	12
Evaluation of the <i>ATM</i> L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms	12
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia	12
Depletion of the RNA binding protein QKI and circular RNA dysregulation in T-cell acute lymphoblastic leukemia	12
Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective coho	12
Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment	12
Preventing central nervous system spread in diffuse large B-cell lymphoma – novel approaches needed	12
Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia	12
Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis	12
B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/βresponse in bone marrow-derived mesenchymal stroma	12
Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia	12
Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical <i>STIL</i>::<i>TAL1</i> fusion events	12
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis	12
Hematopoietic cell transplants for acute leukemias	11
Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment	11
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis	11
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse	11
Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant	11
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies	11
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t	11
Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm	11
Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?	11
Treatment of drug-induced immune thrombocytopenias	11
Intricacies of GATA-ca, continued	11
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual di	11
Do older patients truly benefit from advances in myeloma care?	10
Nandrolone decanoate: new therapeutic option for telomeropathies?	10
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials	10
Beyond adenosine triphosphate: unveiling the pleiotropic effects of pyruvate kinase activation in sickle cell anemia	10
Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience	10
Co-stimulatory and immune checkpoint molecules are important in the tumor microenvironment of Hodgkin-like adult T-cell leukemia/lymphoma	10
One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy	10
Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia	10
Evolution in treatment of acute promyelocytic leukemia: a major victory	10
Expanding the bacterial origins of nodular lymphocyte-predominant Hodgkin lymphoma	10
Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample	10
Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia	10
Anatomy of a crime: how IL7R and NRAS join forces to drive T-cell acute lymphoblastic leukemia	10
Differential transcriptional control of hematopoiesis in congenital and cycling neutropenia patients harboring <i>ELANE</i> mutations	10
Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity	10
For older adults with hematologic malignancies, a comprehensive geriatric assessment matters	10
TENT5C/FAM46C modulation <i>in vivo</i> reveals a trade-off between antibody secretion and tumor growth in multiple myeloma	10
HLA-C*04:09N is expressed at the cell surface and triggers peptide-specific T-cell activation	10
A case series of patients with β-thalassemia trait and iron overload: from multifactorial hepcidin suppression to treatment with mini-phlebotomies	10
A Pin1/PML/P53 axis activated by retinoic acid in <i>NPM-1c</i> acute myeloid leukemia	10
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes	10